Patent US5147289A successfully refreshed from Google Patents.
US5147289A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Non-specific immune system enhancement
Assignee: THEREAKOS Inc A CORP OF FL
•
Filing: 1990-03-29
•
Granted: 1992-09-15
•
Expires: 2010-03-29
Abstract
Abstract The present invention pertains to a method for non-specifically enhancing the immune system response of a mammal to an antigen which comprises the steps of (a) withdrawing leukocyte containing material from the mammal, (b) treating the withdrawn leukocytes in a manner to alter the cella, and (c) returning the treated leukocytes to the mammal. The one embodiment, the method for non-specifically enhancing the immune system response of a mammal is carried out in conjunction with artificially contacting the mammal's immune system with an antigen for a suitable period of time to stimulate the immune system. In another embodiment, the mannal's immune system is naturally exposed to the antigen prior to the non-specific enhancement of the immune system. In yet another embodiment, the invention is directed at a method for preparing an autologous non-specific leukocyte adjuvant.
Inventors
- 👤 Richard L. Edelson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:08
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/39; A61K40/00; A61K40/10; A61K40/11; A61K40/20; A61K40/22; A61K40/40; A61K40/41; A61K40/416; A61K40/418; A61K40/48; A61K41/00; A61K41/0023; A61K41/10; A61K41/17; A61M; A61M1/00; A61M1/36; A61M1/3687; C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0634; C12N5/0636; A61M1/3621; A61M1/3622; A61M1/36226; A61M1/362262; A61M2202/00; A61M2202/04; A61M2202/0413; A61M2202/0439; Y; Y10; Y10S; Y10S424/00; Y10S424/81
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
77 words
A method for non-specifically enhancing the immune system response of a mammal to an antigen which comprises the steps of: (A) enhancing the immune system response by: (a) withdrawing leukocyte containing material from the mammal, (b) treating the withdrawn leukocytes in a manner to alter the cells, (c) returning the treated leukocytes to the mammal, and (B) artificially contacting the mammal's immune system with the antigen for a suitable period of time to stimulate the immune system.
Claim 2
Independent Claim
77 words
A method for non-specifically enhancing the immune system response of a mammal to an antigen which comprises the steps of: (A) enhancing the immune system response by: (a) withdrawing leukocyte containing material from the mammal, (b) treating the withdrawn leukocytes in a manner to alter the cells, (c) returning the treated leukocytes to the mammal, and (B) artificially contacting the mammal's immune system with the antigen for a suitable period of time to stimulate the immune system.
Claim 3
Dependent Claim
15 words
The method according to claim 1, wherein steps (A) and (B) are carried out simultaneously.
Claim 4
Dependent Claim
12 words
The method according to claim 1, wherein the mammal is a human.
Claim 5
Dependent Claim
30 words
The method according to claim 1, wherein the leukocyte containing material in step (A)(a) is selected from the group consisting of blood, lymph fluid, bone marrow, and lymphatic organ tissue.
Claim 6
Dependent Claim
14 words
The method according to claim 1, wherein the leukocytes in step (A)(a) are lymphocytes.
Claim 7
Dependent Claim
11 words
The method according to claim 5, wherein the lymphocytes are T/cells.
Claim 8
Dependent Claim
25 words
The method according to claim 1, wherein the treatment of the leukocytes in step (A)(b) alters the structure of the cell membranes of the leukocytes.
Claim 9
Dependent Claim
25 words
The method according to claim 1, wherein the treatment of the leukocytes in step (A)(b) alters the DNA or the cytoplasmic proteins of the leukocytes.
Claim 10
Dependent Claim
29 words
The method according to claim 1, wherein the treatment of the leukocytes in step (A)(b) comprises irradiating the leukocytes with ultraviolet radiation in the presence of a photoactivatable agent.
Claim 11
Dependent Claim
19 words
The method according to claim 9, wherein the photoactivatable agent is administered to the mammal prior to step (A)(a).
Claim 12
Dependent Claim
19 words
The method according to claim 1, wherein the antigen in step (B) is in the form of a vaccine.
Claim 13
Dependent Claim
21 words
The method according to claim 1, wherein the antigen in step (B) is associated with a deficiency in the immune system.
Claim 14
Dependent Claim
15 words
The method according to claim 12, wherein the antigen is associated with an immunodeficiency disease.
Claim 15
Dependent Claim
31 words
The method according to claim 13, wherein the immunodeficiency disease is selected from the group consisting of acquired immunodeficiency syndrome (AIDS), cancer, immunodeficiency of old age, and immunodeficiency following immunosuppressive therapy.
Claim 16
Dependent Claim
18 words
The method according to claim 1, wherein the antigen in step (B) is associated with a hypersensitivity disease.
Claim 17
Dependent Claim
31 words
The method according to claim 1, wherein the hypersensitivity disease is selected from the group consisting of delayed-type hypersensitivity reaction, autoimmune disease, allergy, infectious disease, rejection of allografts and graft-versus-host reaction.
Claim 18
Dependent Claim
54 words
The method according to claim 9, wherein step (A) (b) comprises the steps of: (1) forming the withdrawn leukocytes into an extracorporeal stream, (2) flowing the stream through a treatment chamber substantially transparent to ultraviolet radiation, and (3) irradiating the stream in the chamber with ultraviolet radiation in the presence of the photoactivatable agent.
Claim 19
Dependent Claim
36 words
The method according to claim 17, wherein the withdrawing of leukocyte containing material, the treating of the withdrawn leukocytes, and the returning of the treated leukocytes to the mammal is carried out as a continuous operation.
Claim 20
Independent Claim
55 words
A method for improving vaccine therapy in a mammal, comprising: a) withdrawing leukocyte containing material from the mammal prior to administration of a vaccine to the mammal; b) treating the withdrawn leukocytes in a manner to alter the cells; c) returning the treated leukocytes to the mammal; and d) administering the vaccine to the mammal.
Claim 21
Independent Claim
55 words
A method for improving vaccine therapy in a mammal, comprising: a) withdrawing leukocyte containing material from the mammal prior to administration of a vaccine to the mammal; b) treating the withdrawn leukocytes in a manner to alter the cells; c) returning the treated leukocytes to the mammal; and d) administering the vaccine to the mammal.
References Cited (Backward Citations)
US4824432A
Cited
US4664913A
Cited
US4664913B1
Cited
US4634417A
Cited
US4955857A
Cited
US4960408A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-09-15 | 1996-03-16 | 1996-09-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-09-15 | 2000-03-16 | 2000-09-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-09-15 | 2004-03-16 | 2004-09-15 | $7700.00 | Window Closed / Lapsed |